26 percent of senior oncology patients use alternative therapies
the ONA take:
More than a quarter of senior oncology patients use complementary or alternative medicines (CAM), according to a study published in the Journal of Geriatric Oncology.
"Currently, few oncologists are aware of the alternative medicines their patients take," says Ginah Nightingale, PharmD, an Assistant Professor in the Jefferson College of Pharmacy at Thomas Jefferson University.
"Patients often fail to disclose the CAMs they take because they think they are safe, natural, nontoxic and not relevant to their cancer care, because they think their doctor will disapprove, or because the doctor doesn't specifically ask."
For the study, researchers surveyed senior patients with cancer who came for consultations at the Thomas Jefferson University Hospital Senior Adult Oncology Multi-Disciplinary clinic. Researchers found that 26% of patients were taking CAMs at some point during their cancer care. Of those, 68% were over 80 years of age and the majority of users were women.
The most common CAMs used by patients were alternative therapies for macular degeneration, probiotics, joint health, and mega-dose vitamins or minerals.
The finidngs suggest that it is very important that clinicians comprehensively screen older patients with cancer for all medications used, including CAMs. Certain CAMs like St. John's wort can interact with certain anti-cancer medications, making them less effective.
More than a quarter of senior oncology patients use complementary or alternative medicines (CAM).
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|